News and Announcements
Quixxi’s Venture Partner, Lakeba Group, supported by Grant Thornton
- Published August 30, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Lakeba’s Future Hub has a vision to provide a one stop shop solution for businesses who want to adopt blockchain solutions.
- Grant Thornton’s support allows Lakeba Future Hub to deliver expert services to drive growth of blockchain developments in this market and abroad.
The distinguished tax and advisory firm Grant Thornton announced their recent support for Australian technology innovator Lakeba Group. Lakeba’s Future Hub has a vision to provide a one stop shop solution for businesses who want to adopt blockchain solutions. The company brings together expert partners and international market leaders in technology, legal, education, and taxation.
The CEO of Lakeba Group greatly supports collaboration with Grant Thornton because the company “will be greatly strengthened with the proven taxation authority and accounting governance leadership Grant Thornton brings to the table.”
Grant Thornton’s support allows Lakeba Future Hub to deliver expert services to drive growth of blockchain developments in this market and abroad. Business organisations will be able to grow in an ecosystem that delivers three important aspects: legal, taxation, and technology development. Since Lakeba Future Hub launched in July, they have been expanding quickly and strengthening blockchain development.
Register your interest in Quixxi below.
About Quixxi
Quixxi is one of Lakeba’s business ventures that is building a marketplace to integrate blockchain services, enabled by a new tradeable cryptocurrency called Quixxi Token (QXE).
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
